-
2023-503422-39-00
5
2023-10-20
Hepatocellular Carcinoma (HCC)
-
2022-501343-33-00
5
2023-10-18
Biochemically recurrent prostate cancer
-
2023-506821-12-00
5
2023-10-12
Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Me
-
2023-504028-24-00
5
2023-09-22
Large B-Cell Lymphoma
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2022-501176-26-00
5
2023-08-04
Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-511654-42-00
5
2023-06-28
Spinal Muscular Atrophy (SMA)
-
2023-506269-78-00
5
2023-06-20
CDKL5 Deficiency disorder
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2024-510742-13-00
5
2023-04-19
Pediatric low-grade glioma harboring an activating RAF alteration requ
-
2023-506616-41-00
5
2023-03-31
Lennox-Gastaut syndrome (LGS)
-
2023-505211-21-00
4
2023-03-10
Previously untreated locally advanced or metastatic non-small cell lun
-
2023-508350-26-00
5
2023-03-02
Fibrodysplasia Ossificans Progressiva
-
2024-514173-22-00
5
2023-02-28
Cystic Fibrosis
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2023-510351-31-00
7
2023-01-06
Duchenne muscular dystrophy
-
2023-505057-40-00
4
2022-12-02
Lung Cancer, Non-Small Cell
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-515637-14-00
5
2022-11-08
Cystic Fibrosis
-
2024-514394-22-00
6
2022-10-24
Actinic Keratosis
-
2023-508265-33-00
5
2022-10-13
Vasomotor symptoms caused by adjuvant endocrine therapy in women with,